Niklaus Meier

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Comment on "Meta-Analysis of Cost-Effectiveness" by Bang and Zhao: Combinability, Joint Modeling, and a Two-Stage Framework for Cost-Effectiveness Analysis Synthesis.

Comment on "Meta-Analysis of Cost-Effectiveness" by Bang and Zhao: Combinability, Joint Modeling, and a Two-Stage Framework for Cost-Effectiveness Analysis Synthesis.

Journal: Statistics in medicine
Published: March 31, 2026

The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions.

The Use of Baseline Score in Cost-Effectiveness Modeling of Competing Interventions.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: September 05, 2025

Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations.

Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations.

Journal: PharmacoEconomics
Published: March 15, 2025

Title Not Found

Title Not Found

Journal: Revue medicale suisse
Published: February 20, 2025

Systematic review of cost-effectiveness modelling studies for haemophilia.

Systematic review of cost-effectiveness modelling studies for haemophilia.

Journal: Journal of medical economics
Published: December 18, 2024

Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland.

Reply to comment by Arber C, et al. on: Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland.

Journal: Swiss medical weekly
Published: October 28, 2024

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Journal: PharmacoEconomics - open
Published: February 25, 2024

Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.

Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data.

Journal: Swiss medical weekly
Published: September 29, 2023

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.

Journal: PharmacoEconomics
Published: July 18, 2023

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Journal: The journal of headache and pain
Published: December 19, 2022

Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease.

Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: July 29, 2022

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.

Journal: The journal of headache and pain
Published: July 26, 2022
Showing 1-12 of 31

Last Updated: 09/26/2026